In order to support the implementation of health services for the health insurance program and the signing of the Minister of Health Decree number HK.01.07/MENKES/1276/2023 concerning the Value of Drug Price Claims for the Referral Program, Chronic Disease Drugs at Advanced Referral Health Facilities, Chemotherapy Drugs, and Alteplase Drugs which also revokes the Minister of Health Decree Number HK.01.07/MENKES/1984/2022 concerning the Value of Drug Price Claims for the Referral Program, Chronic Disease Drugs at Advanced Referral Health Facilities, and Chemotherapy Drugs. .07/MENKES/1984/2022 on the Value of Drug Price Claims for the Referral Program, Chronic Disease Drugs at Advanced Referral Health Facilities, and Chemotherapy Drugs, the Directorate General of Pharmaceuticals and Medical Devices held dissemination activities on the Value of Drug Price Claims for the Referral Program, Chronic Disease Drugs at Advanced Referral Health Facilities (FKRTL), Chemotherapy Drugs, and Alteplase Drugs and the fulfillment of JKN drug needs to relevant stakeholders.

The stipulation of the Minister of Health Decree is a mandate from Presidential Regulation Number 82 of 2018 concerning Health Insurance and Permenkes Number 3 of 2023 concerning Health Service Tariff Standards in the Implementation of the Health Insurance Program, where the value of drug claims for Referral Program Drugs, Chronic Disease Drugs at FKRTL, Chemotherapy Drugs and Alteplase Drugs, is determined by the Minister as a reference for health facilities to bill claims to BPJS Health.

Under the Decree, the Ministry of Health has established separate drug price claim values for 392 drug items, and will carry out a consolidation process for 89 drug items that have not yet been determined so that the drug price claim values can be established soon.

The dissemination activity at Le Meridien Hotel Jakarta on April 13, 2023 was conducted in a hybrid manner. The event was attended by the Director of Health Service Insurance, BPJS Kesehatan, Head of the Bureau of Goods and Services Procurement, Ministry of Health, GP Pharmacy Production and Distribution Division, Vertical Hospitals and all hospitals that collaborate with BPJS, HISFARSI PP IAI, Indonesian Hospital Association (PERSI), Asosiasi RS Vertikal Indonesia (ARVI), Asosisasi Rumah Sakit Daerah Seluruh Indonesia (ARSADA), Persatuan Ahli Farmasi Indonesia (PAFI), HISFARSI PD IAI Jakarta, Gabungan Perusahaan Farmasi Indonesia (GPFI), International Pharmaceutical Manufacturers Group (IPMG) and opened by the Director General of Pharmaceuticals and Medical Devices.

In her opening remarks, she advised to continue to make efforts to improve the quality of pharmaceutical services in accordance with the health transformation agenda that has been launched by the Ministry of Health, especially the second transformation agenda, namely the transformation of the referral health service system.

 "We want the community to get quality health services including pharmaceutical services that are equivalent to quality hospitals in other countries, so that none of our people seek treatment abroad and prefer treatment in our country," concluded Director General Rizka.

The event continued with a discussion session presented by speakers including the Directorate of Pharmaceutical Production and Distribution, Bureau of Goods and Services Procurement of the Ministry of Health, BPJS Kesehatan, GP Pharmacy and IPMG.

The Ministry of Health will continue to monitor and encourage the fulfillment of JKN drug needs by the Pharmaceutical Industry in order to increase drug availability to drug access in the community so as to improve public health status in accordance with the health transformation that has been launched by the Ministry of Health.